대만성 조현병 환자에서 12주 체중관리 프로그램이 삶의 질에 미치는 영향

키워드

참고문헌 (38)

1. Allison DB, "Antipsychotic-induced weight gain: A comprehensive research synthesis", Am J Psychiatry, 156, pp.1686~1696 (1999)
2. Ryan MC, "Physical consequences of schizophrenia and its treatment: The metabolic syndrome", Life Sci, 71, pp.239~257 (2002)
3. Zimmermann U, "Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients", J Psychiatr Res, 37, pp.193~220 (2003)
4. Baptista T, "Treatment of the metabolic disturbances caused by antipsychotic drugs: Focus on potential drug interactions", Clin Pharmacokinet, 43, pp.1~15 (2004)
5. Melkersson K, "Adverse metabolic effects associated with atypical antipsychotics: Literature review and clinical implications", Drugs, 64, pp.701~723 (2004)
6. Hoebel BG, "Brain microdialysis as a molecular approach to obesity serotonin dopamine cychc-AMP, In In Obesity towards a molecular approach", pp.45~62 (1989), Wiley-Liss
7. Parada MA, "Sulpiride injections in the lateral hypothalamus induce feeding and drinking in rats", Pharmacol Biochem Behav, 30, pp.917~923 (1988)
8. Alter GA, "Cholecystokinin attenuates basal and drug-induced increases of limbic and striatal dopamine release", Brain Res, 460, pp.76~82 (1988)
9. Baptista T, "Glucose tolerance and serum insulin levels in an animal model of obesity induced by the antipsychotic drug sulpride", Pharmacol Toxicol, 83, pp.57~61 (1998)
10. Ravussin E., "Metabolic differences and the development of obesity", Metabolism, 44, pp.12~14 (1995)
11. Gerardo-Gottens T, "Prolactin stimulates food intake in a dose-dependent manner", Am J Physiol, 256, pp.276~280 (1989)
12. Ferreira NF, "Endocrine and psychological evaluation of women with recent weight gain", Psychoneuroendocrinology, 20, pp.53~63 (1995)
13. Baptista T, "Prevalence of obesity in outpatients receiving antipsychotic drugs correlation with serum prolactine levels", Caracas, Venezuela Regional Symposium of the World Federation of Societies of Biological Psychiatry Catacas, pp.17~ (1998), Venezuelan Psychiatric Association Press
14. Foss MC, "Pheripheral glucose metabolism in human hyperprolactinemia", Chn Endocrinol, 43, pp.721~726 (1995)
15. Homel P, "Changes in body mass index for individuals with and without schizophrenia, 1987-1996", Schizophr Res, 55, pp.277~284 (2002)
16. Foreyt J, "The ultimate trumph of obesity", Lancet, 346, pp.34~35 (1995)
17. Perkins DO, "Adherence to antipsychotic medications", J Clin Psychiatry, 60(suppl 21), pp.25~30 (1999)
18. Faulkner G, "Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications", Can J Psychiatry, 51, pp.502~511 (2006)
19. Faulkner G, "Schizophrenia and weight management: a systematic review of interventions to control weight", Acta Psychiatr Scand, 108, pp.324~332 (2003)
20. Werneke U, "Behavioral management of antipsychotic-induced weight gain: a review", Acta Psychiatr Scand, 108, pp.252~259 (2003)
21. Evans S, "Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial", Aust N Z J Psychiatry, 39, pp.479~486 (2005)
22. Brown C, "A psychiatric rehabilitation approach to weight loss", Psychiatr Rehabil J, 29, pp.267~273 (2006)
23. Dunbar GC, "The development of SBQOL - A unique scale for measuring quality of life", Brit J Med Econo, 2, pp.65~74 (1992)
24. World Health Organization, "WHOQOL Study Protocol" (1993), WHO
25. Yoon JS, "A preliminary study on Korean Version of the SmithKlein Beecham Quality of Life Scale (KvSBQOL)", J Korean Neuropsychiatr Assoc, 37, pp.280~294 (1998)
26. Hunt SM, "Measuring quality of life in psychiatry. In: Quality of Life Assessment: Key Issue in the 1990s", pp.343~354 (1990), Kluwer Academic Publishers
27. Norman RM, "The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the quality of Life Scale", Acta Psychiatr Scand, 102, pp.303~309 (2000)
28. Meltzer HY, "Outcome in schizophrenia: beyond symptom reduction", J Clin Psychiatry, 60, pp.32~35 (1999)
29. Cramer JA, "Quality of life in schizophrenia: a comparison of instruments. Department of Veterana Affairs Cooperative Study Group on Clozapine in refractory schizophrenia", Schizophr Bull, 26, pp.659~666 (2000)
30. Breier A, "Olanzapine versus ziprasidone: result of a 28-week double-blind study in patients with schizophrenia", Am J Psychiatry, 162, pp.1879~1887 (2005)
31. Overall JE, "The brief psychiatric rating scale", Psychol Rep, 10, pp.799~812 (1962)
32. Rosenberg M, "Society and Adolescent self-image" (1965), Princeton University Prese
33. Dunbar GC, "The development of SBQOL - A unique scale for measuring quality of life", Brit J Med Econo, 2, pp.65~74 (1992)
34. Stoker MJ, "The SmithKlein Beecham ‘quality of life’ scale: A validation and reliability study inpatients with affective disorder", Qual Life Res, 1, pp.385~395 (1992)
35. 김진훈, "한국어판 정신분열병 삶의 질 척도의 개발과 PANSS와의 관련성", 신경정신의학, 45(5), pp.401~410 (2006), 대한신경정신의학회
36. Wilkinson G, "Self-report quality of life measure for people with schizophrenia: the SQLS", Br J Psychiatry, 177, pp.42~46 (2000)
37. lean ME, "Sibutramine a review of clinical efficacy", Int J Obes Relat Metab Disord, 21, pp.30~36 (1997)
38. Goodall E, "A clinical trial on the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity", Br J Psychiatry, 153, pp.209~213 (1988)

관련 논문AI추천